医药政策法规
- (2022-02-13)
- (2022-02-12)
改变ALK阳性肺癌的一线临床实践!辉瑞第三代ALK抑制剂Lorviqua(劳拉替尼)获欧盟批准:疗效明显优于Xalkori!
(2022-02-12)- (2022-02-12)
- (2022-02-11)
- (2022-02-11)
- (2022-02-11)
- (2022-02-11)
- (2022-02-11)
- (2022-02-11)
- (2022-02-10)
- (2022-02-10)
- (2022-02-10)
- (2022-02-10)
- (2022-02-09)
- (2022-02-09)
- (2022-02-09)
- (2022-02-09)
- (2022-02-09)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-08)
- (2022-02-07)
- (2022-02-07)
- (2022-02-07)
- (2022-02-06)
- (2022-02-06)
- (2022-02-06)
- (2022-02-06)
- (2022-02-06)
- (2022-02-06)
- (2022-02-05)
- (2022-02-05)
- (2022-02-05)
- (2022-02-05)
- (2022-02-05)
- (2022-02-05)
- (2022-02-04)
- (2022-02-04)
- (2022-02-04)
- (2022-02-04)
- (2022-02-04)
- (2022-02-03)
- (2022-02-03)
- (2022-02-03)
- (2022-02-03)
- (2022-02-03)
- (2022-02-03)
- (2022-02-02)
- (2022-02-02)
- (2022-02-02)